Fluticasone propionate/salmeterol - Orion

Drug Profile

Fluticasone propionate/salmeterol - Orion

Alternative Names: Easyhaler salmeterol-fluticasone; Salmeterol/Fluticasone Easyhaler; Salmetrol/fluticasone propionate-Orion

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Mar 2018 Orion receives positive conclusions for the salmeterol-fluticasone combination for Asthma and Chronic obstructive pulmonary disease under the EU's decentralised procedures (DCP)
  • 19 Dec 2017 Orion completes the phase I SAIMI trial for Asthma (In volunteers) in Finland (NCT03238482)
  • 16 Aug 2017 Orion initiates enrolment in the phase I SAIMI trial for Asthma (In volunteers) in Finland (NCT03238482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top